A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

PHASE2UnknownINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

May 23, 2019

Primary Completion Date

December 31, 2021

Study Completion Date

July 31, 2022

Conditions
Cervical Cancer
Interventions
BIOLOGICAL

GB226

GB226 is administrated at the dose of 3mg/kg, once per 2 weeks (±3 days), and distributed in 100ml of 0.9% sodium chloride solution. The concentration of GB226 shall be strictly controlled at 1mg/ml\~10mg/ml, the duration is 60 min (±10 min) for the first infusion of the drug, and can be reduced to 30 min (±10 min) for the subsequent infusion of the drug if there is infusion related adverse reaction.

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing

Sponsors
All Listed Sponsors
lead

Genor Biopharma Co., Ltd.

INDUSTRY